Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response.

Acute myeloid leukemia (AML) is cancer that affects the blood and bone marrow. Doctors may recommend blood transfusions as part of AML treatment. The specific transfusion type and associated risks ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.

Although randomized studies comparing different anthracyclines have been conducted, it is still unresolved whether any specific anthracycline is more effective or causes less long-term cardiac ...